Stock N1BI34 NEUROCRINE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Neurocrine Biosciences, Inc. Sao Paulo

Equities

N1BI34

BRN1BIBDR009

Market Closed - Sao Paulo
Other stock markets
 16:03:54 26/06/2024 BST 		5-day change 1st Jan Change
37 BRL +8.00% Intraday chart for Neurocrine Biosciences, Inc. +2.78% +14.55%
06-13 Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-13-2024 10:40 AM
06-05 Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing
MT
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating
MT
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing
MT
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing
MT
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating
MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating
MT
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170
MT
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept
MT
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating
MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating
MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating
MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating
MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating
MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating
MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $140 From $127, Maintains Equalweight Rating
MT
Wedbush Adjusts Neurocrine Biosciences' Price Target to $147 From $141, Keeps Outperform Rating
MT
Goldman Sachs Raises Price Target on Neurocrine Biosciences to $153 From $134, Maintains Buy Rating
MT
Barclays Raises Neurocrine Biosciences' Price Target to $150 From $145, Maintains Overweight Rating
MT
RBC Raises Price Target on Neurocrine Biosciences to $129 From $121, Keeps Sector Perform Rating
MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $144 From $141, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. N1BI34 Stock
  5. News Neurocrine Biosciences, Inc.
  6. Analyst Reco.